Study identity card

Grimberg

Israel
Share
  • Study type: Randomised Clinical Trial, Treatment
  • Study type descriptors: Randomised controlled trial, Single centre
  • Objective: To assess the safety and tolerability of an intranasal siRNA against SARS-CoV-2 (Apo-Si-K170A-C76) in healthy adults
  • Number of participants enrolled: 56
  • Study enrolling from to
  • Study includes follow-up for 5 days

Study Data

  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Apo-Si-K170A-C76

Other information

If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it

The data is updated up to